We are live on ! Find out more
ABOS icon

Acumen Pharmaceuticals
ABOS

84 hedge funds and large institutions have $109M invested in Acumen Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 31 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 7

158% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 12

44% more capital invested

Capital invested by funds: $75.2M → $109M (+$33.3M)

18% more funds holding

Funds holding: 71 → 84 (+13)

4.83% more ownership

Funds ownership: 58.87% → 63.7% (+4.8%)

31% less call options, than puts

Call options by funds: $246K | Put options by funds: $355K

Holders
84
Holders Change
+13
Holders Change %
+18.31%
% of All Funds
1.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
31
Reduced
12
Closed
7
Calls
$246K
Puts
$355K
Net Calls
-$109K
Net Calls Change
-$179K

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$15.5M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$3.86M
3
ACM
ADAR1 Capital Management
Texas
+$3.23M
4
IC
Ikarian Capital
Texas
+$2.04M
5
Two Sigma Investments
Two Sigma Investments
New York
+$989K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.22M
2
Citadel Advisors
Citadel Advisors
Florida
-$881K
3
LCM
Laurion Capital Management
New York
-$871K
4
Jane Street
Jane Street
New York
-$134K
5
XT
XTX Topco
Cayman Islands
-$105K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
26
Bridgeway Capital Management
Texas
$416K +$15.3K +6,000 +4%
State Street
27
State Street
Massachusetts
$358K +$131K +51,550 +51%
Morgan Stanley
28
Morgan Stanley
New York
$341K -$56.9K -22,321 -13%
Qube Research & Technologies (QRT)
29
Qube Research & Technologies (QRT)
United Kingdom
$284K +$185K +72,403 +151%
Dimensional Fund Advisors
30
Dimensional Fund Advisors
Texas
$282K +$180K +70,694 +144%
CFP
31
Catalyst Financial Partners
Massachusetts
$212K – – –
Jane Street
32
Jane Street
New York
$212K -$134K -52,462 -37%
PI
33
PFG Investments
New York
$191K +$158K +61,850 +326%
Northern Trust
34
Northern Trust
Illinois
$178K – – –
Point72 Asset Management
35
Point72 Asset Management
Connecticut
$159K +$79.1K +31,010 +85%
PFS
36
Prospera Financial Services
Texas
$118K – – –
CFM
37
Catalyst Funds Management
Australia
$108K +$40.8K +16,000 +54%
VA
38
Verdad Advisers
Massachusetts
$88K +$95.1K +37,278 New
UBS Group
39
UBS Group
Switzerland
$87.7K +$39.8K +15,584 +72%
RC
40
Rangeley Capital
Connecticut
$82.6K +$89.3K +35,000 New
Barclays
41
Barclays
United Kingdom
$72.4K +$1.75K +688 +2%
IFPG
42
Intrepid Financial Planning Group
Indiana
$71.2K – – –
OAC
43
OMERS Administration Corp
Ontario, Canada
$67.5K +$15.7K +6,146 +27%
AC
44
AXQ Capital
New Jersey
$67.2K +$72.7K +28,487 New
IAA
45
Independent Advisor Alliance
North Carolina
$44.8K – – –
PA
46
Pinnacle Associates
New York
$42.5K – – –
PWMAG
47
Pinnacle Wealth Management Advisory Group
New Jersey
$42.5K – – –
American Century Companies
48
American Century Companies
Missouri
$42.3K +$45.7K +17,929 New
Simplex Trading
49
Simplex Trading
Illinois
$41.1K +$44.4K +17,414 New
CA
50
Clune & Associates
Illinois
$38.9K – – –
1
2
3 4

ABOS Hedge Fund Activity: Q1 2026 in Review

84 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q1 2026, worth a combined $109M — up 44% from $75.2M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ABOS positions and 7 closed out — a net gain of 14 holders — while 31 added to existing stakes and 12 trimmed.

The largest buyer was RA Capital Management, adding an estimated $15.5M. The largest seller was Fidelity Investments, cutting an estimated $2.22M.

  • 84 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q1 2026, up from 71 in Q4 2025.
  • Funds reported $109M of Acumen Pharmaceuticals stock for Q1 2026, up 44% quarter-over-quarter.
  • 21 funds opened new Acumen Pharmaceuticals positions in Q1 2026 and 7 closed out, a net change of +14 holders.
  • The largest Acumen Pharmaceuticals buyer in Q1 2026 was RA Capital Management, an estimated $15.5M added.
  • The largest Acumen Pharmaceuticals seller in Q1 2026 was Fidelity Investments, an estimated $2.22M sold.

Based on aggregated 13F filings for Q1 2026.